18
October

06:00 PM EST

Discover How Cutting Edge Epigenetic Technologies are Shaping The Future of Biomarker Driven Clinical Trial Design

Boston Chops, 52 Temple Pl, Boston, MA 02111, United States

What to expect

Overview of Discussion

Join leading experts in clinical epigenetics and assay development for a collaborative discussion exploring the latest trends in epigenetic drug and biomarker innovation.

Engage in a focused discussion on how nucleosome-based markers are poised to accelerate oncology clinical trials, offering broader applications for monitoring both toxicity and efficacy.

By the end of this discussion, attendees will:
-Gain a nuanced understanding of the emerging opportunities in biomarker-driven,
epigenetic therapeutic development.
-Acquire insights into the future potential of nucleosome markers as versatile tools
for toxicity and response monitoring.

Agenda

Next-Generation Quantitative Epigenetic Immunoassay Development
In Vivo and Ex Vivo Nucleosome Profiling in Epigenetic Therapeutic Discovery
In Vitro and Clinical Nucleosome Pharmacodynamics Assays

Nucleosomes as Toxicity Markers and Surrogate Endpoints in Oncology Trials
Neutrophil Extracellular Traps: Acute Phase Response Markers
Nucleosomes as Novel Markers for NETs
NETosis as a Driver for Metastasis

Meet the Facilitators

The Dinner will be lead by our expert facilitators

Mark Eccleston

Chief Technology Officer VolitionRx

Terry Kelly

Chief Scientific Officer of Volition America, Chief Innovation Officer of Volition Rx Volition

White Papers

White Paper

A valuable tool from target identification to validation in clinical studies.

Empowering drug developers and scientists through a range of state-of-the-art assays for rapid epigenetic profiling in disease, model development, preclinical testing, and clinical studies –from discovery to market ready.

Overview

White Paper

Using Nu.Q® Discover to profile histone post-translational modifications following treatment with epigenetic inhibitors.

Nu.Q® Discover Cell Culture White Paper Brandi Atteberry, Dorian Parmart, Justin Cayford, Terry Kelly

Overview

More about Volition

More information

Volition is at the forefront of epigenetic immunoassay development, contributing to the drug discovery and development cycle from in-vitro target validation to human clinical trials. Our assays, widely used in oncology and immunotherapy, focus on delivering actionable insights to streamline the entire drug development process. Nu.Q® Discover assays have been validated in preclinical PD studies tracking epigenetic modification levels in response to epigenetic inhibitors with recent data presented at AACR demonstrating a dose-dependent reduction in specific Histone PTM levels by simple liquid biopsy. Our NETosis assay measures the release of Neutrophil Extracellular Traps, aiding in the assessment of acute inflammatory conditions like sepsis and cancer. Our Ex-vivo – Synthetic Sepsis™ platform is designed to screen NETosis modulators and potential activators, providing ex-vivo human data ahead of First-in-Human (FIH) studies. For specialized requirements, we can develop new assays following CLSI development guidelines. Our R&D activities are anchored in Belgium, complemented by an innovation lab in California and offices in Texas, London, and Singapore. For more details and scientific data please visit, volition.com.

Location

Boston Chops, 52 Temple Pl, Boston, MA 02111, United States

Here To Help

Want to know more? Interested in sponsoring the event? Need help registering your team? Just get in touch and a member of the team will be happy to help.

Europe

USA East

USA West

Webinars

Dinners & Spotlights

R&D

R&D Volition

Discover How Cutting Edge Epigenetic Technologies are Shaping The Future of Biomarker Driven Clinical Trial Design

<img class="lazy" decoding="async" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%2012%2016'%3E%3C/svg%3E" data-src="https://proventainternational.com/wp-content/uploads/2020/12/location.png" >Boston Chops, 52 Temple Pl, Boston, MA 02111, United States

Overview of Discussion

Agenda

Meet the Facilitators

Mark Eccleston

Terry Kelly

White Papers

A valuable tool from target identification to validation in clinical studies.

Using Nu.Q® Discover to profile histone post-translational modifications following treatment with epigenetic inhibitors.

More about Volition

Location

Here To Help

Select days you wish to attend You can add multiple days

VAT Excluded

Select days you wish to attend You can add multiple days

Pass includes:

VAT Excluded

About You

Your Address

About Your Company

This is required field*

Bone/Osteoporosis

Immunology

Orthopaedics

Cardiovascular

Infectious diseases

Pulmonology

CNS

Inflammation

Psychiatry

Dermatology

Internal diseases

Respiratory

Diabetes

Metabolic diseases

Rheumatology

Endocrinology

Nephrology

Surgery

ENT

Neurology

Urology

Gastroenterology

Oncology

Vaccines

Haematology

Ophthalmology

Thrombosis

Rare Diseases

This is required field*

0-10

10-50

50-100

100-500

500+

This is required field*

This is required field*

Under £100,000

£100,000 - £500,000

£500,000 - £1,000,000

£1,000,000 - £5,000,000

£5,000,000 - £10,000,000

£10,000,000 +

This is required field*

This is required field*

Discovery to Development

Pre-Clinical

Phase 1

Phase 2

Phase 3

Phase 4

This is required field*

Boston Chops, 52 Temple Pl, Boston, MA 02111, United States